Hypogonadism – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Hypogonadism
in men, defined by a low serum testosterone concentration, causes a slew of
symptoms such as decreased libido, erectile dysfunction, reduced ejaculate
volume, loss of body and facial hair, weakness, decreased lean body mass,
reduced bone density, increased body fat, fatigue, and anemia. Most notably,
libido loss and erectile dysfunction (ED). Depressive symptoms, decreased
cognitive abilities, irritability, and lethargy or energy loss are also signs
of low testosterone. Endogenous testosterone deficiency also has a negative
impact on bone mass and is a significant risk factor for osteoporosis in men.
Progressive loss of muscle mass and strength and testicular dysfunction often
results in impaired sperm production. Unlike female menopause, which is a
universal and abrupt aging process, not all men become testosterone deficient
as they age. Even in their advanced years, a significant number of men remain
eugonadal. However, as men age, they become increasingly likely to have
conditions, such as cardiovascular disease, depression, osteoporosis, and
diabetes, that occur concomitantly with decreased testosterone levels.
·
The prevalent cases of Hypogonadism affect an
estimated 4 to 5 million men in the United States, although it may occur in men
at any age.
·
Hypogonadism was found in 2.1 percent to 12.8
percent of middle-aged to older men in the general population, with an
estimated incidence of 12 new cases per 1,000 people per year.
·
Patients with comorbid conditions, such as
type 2 diabetes mellitus and obesity, had a higher prevalence. Approximately
10–12% of men with Hypogonadism were being treated with testosterone.
Thelansis’s
“Hypogonadism Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2023 To 2033" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Hypogonadism treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
KOLs insights of Hypogonadism across 8
MM market from the centre of Excellence/ Public/ Private hospitals participated
in the study. Insights around current treatment landscape, epidemiology,
clinical characteristics, future treatment paradigm, and Unmet needs.
Hypogonadism
Market Forecast Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Tags: Hypogonadism,
Hypogonadism market outlook, Hypogonadism competitive landscape, Hypogonadism market forecast, Thelansis, Primary market research, KOL
insights, Competitive Intelligence (CI)
Comments
Post a Comment